Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-29T01:59:32.007Z Has data issue: false hasContentIssue false
  • English
  • Français

Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease

Published online by Cambridge University Press:  24 May 2005

Robert Tulloh ,
Michael Marsh ,
Michael Blackburn ,
Frank Casey ,
Warren Lenney ,
Peter Weller  and
Barry R. Keeton
Robert Tulloh
Affiliation:
Guy's Hospital, London, UK
Michael Marsh
Affiliation:
Southampton General Hospital, Southampton, UK
Michael Blackburn
Affiliation:
Leeds General Infirmary, Leeds, UK
Frank Casey
Affiliation:
Royal Hospital for Sick Children, Belfast, UK
Warren Lenney
Affiliation:
Stoke City General Hospital, Stoke on Trent, UK
Peter Weller
Affiliation:
Birmingham Children's Hospital, Birmingham, UK
Barry R. Keeton
Affiliation:
Southampton General Hospital, Southampton, UK
Get access Rights & Permissions [Opens in a new window]

Abstract

New data are emerging on the use of palivizumab as prophylaxis against infection with the respiratory syncytial virus in infants with congenital cardiac disease. Following a 4-year multicentre randomised trial, it was shown that prophylactic injections with palivizumab were effective and safe for such children. Prophylaxis consists of 5, monthly, intramuscular injections of palivizumab, at a dose of 15 mg/kg, given during the season for infection with the respiratory syncytial virus. Timing is at the discretion of the physician, depending on the onset of the season locally. It is suggested that, in the United Kingdom, this should be commenced in mid-September. To help clinicians to identify appropriate candidates for palivizumab, a working group of the British Paediatric Cardiac Association has developed recommendations.

Infants, namely those under 1 year old, with congenital cardiac disease likely to benefit from prophylaxis include those with haemodynamically significant lesions, particularly increased pulmonary blood flow with or without cyanosis; pulmonary venous congestion, pulmonary hypertension or long-term pulmonary complications, residual haemodynamic abnormalities following medical or surgical intervention (patients who have undergone cardiopulmonary bypass should receive an injection as soon as they are medically stable), cardiomyopathy requiring treatment, and congenital cardiac disease likely to need hospital admission for medical or surgical intervention during the season of infection with the virus. Prophylaxis with palivizumab may also be indicated, at the discretion of the physician, in some children with complex cardiac disease over the age of 1 year. Children less likely to benefit from prophylaxis are those with haemodynamically insignificant disease, or those with lesions adequately corrected by medical or surgical intervention.

Keywords

Respiratory infectionscongenital heart diseasepaediatricsdrug treatment
Type
Original Article
Information
Cardiology in the Young , Volume 13 , Issue 5 , October 2003 , pp. 420 - 423
Copyright
© 2003 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Weigl JA, Puppe W, Schmitt HJ. Seasonality of respiratory syncytial virus-positive hospitalizations in children in Kiel, Germany, over a 7-year period. Infection 2002; 30: 186–192.Google Scholar
Gilchrist S, Török TJ, Gary HE Jr, Alexander JP, Anderson LJ. National surveillance for respiratory syncytial virus, United States; 1985–1990. J Infect Dis 1994; 170: 986–990.Google Scholar
Navas L, Wang E, de Carvalho V, Robinson J and the Pediatric Investigators Collaborative Network on Infections in Canada. Improved outcome of respiratory syncytial virus infection in high-risk hospitalized population of Canadian children. J Pediatr 1992; 121: 348–354.Google Scholar
MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307: 397–400.Google Scholar
Simoes EA. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 2002; 3 (Suppl 1): S26–S33.Google Scholar
Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137: 865–870.Google Scholar
Sigurs N. Clinical perspectives on the association between respiratory syncytial virus and reactive airway disease. Respir Res 2002; 3 (Suppl 1): S8–S14.Google Scholar
Wang EL, Law BJ, Robinson JL, et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) Study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics 1997; 99: E9.Google Scholar
Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med 1999; 27: 1974–1981.Google Scholar
IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531–537.
American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211–1216.
Meissner HC. Study: palivizumab safe for children with CHD. AAP News 2002; 21: 271. www.aapnews.org/cgi/content/short/21/6/271-b.Google Scholar
Carbonell-Estrany X, Guiffré L, Kimpen JLL, et al. Guidelines for the use of Synagis® (palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion. Infect Med 1999; 16 (Suppl G): 29–33.Google Scholar
Joint Committee on Vaccination and Immunisation. Minutes of the meeting held on Friday 1 November 2002. www.doh.gov.uk/jcvi/mins01nov02.htm.
Sondheimer HM, Cabalka AK, Feltes TF, Piazza FM, Connor EM and the Cardiac Synagis Study Group. Palivizumab (PV) reduces hospitalization due to respiratory syncytial virus (RSV) in young children with serious congenital heart disease (CHD). Pediatr Cardiol 2002; 23: 664 (Abstr).Google Scholar
Feltes TF, Cabalka AK, Meissner HC, et al, for the Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatrics 2003; 143: 532–540.Google Scholar
Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001; 85: 463–468.Google Scholar